Impact of contacting study authors to obtain additional data for systematic reviews: Diagnostic accuracy studies for hepatic fibrosis

Systematic Reviews

Volumn 3, Issue 1, 2014, Pages

  Selph, Shelley S ^a   Ginsburg, Alexander D ^a   Chou, Roger ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Contacting study authors; Diagnosing hepatic fibrosis; Hepatitis C infection; Systematic review

Indexed keywords

ARTICLE; AUTHOR; BLOOD ANALYSIS; DIAGNOSTIC ACCURACY; E-MAIL; HUMAN; INFORMATION PROCESSING; INFORMATION SEEKING; INTERPERSONAL COMMUNICATION; LIVER FIBROSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BLOOD; CHRONIC HEPATITIS C; COMPLICATION; COOPERATION; LITERATURE; LIVER CIRRHOSIS; PROCEDURES; RESEARCH; VIROLOGY; WRITING;

BIOLOGICAL MARKER;

AUTHORSHIP; BIOLOGICAL MARKERS; COOPERATIVE BEHAVIOR; DATA COLLECTION; ELECTRONIC MAIL; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; RESEARCH REPORT; REVIEW LITERATURE AS TOPIC;

EID: 84927927348     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/2046-4053-3-107     Document Type: Article

References (88)

1. Gibson CA, Bailey BW, Carper MJ, Lecheminant JD, Kirk EP, Huang G, Dubose KD, Donnelly JE. Author contacts for retrieval of data for a meta-analysis on exercise and diet restriction. Int J Technol Assess Health Care 2006, 22:267-270.
2. Kelley GA, Kelley KS, Tran ZV. Retrieval of missing data for meta-analysis: a practical example. Int J Technol Assess Health Care 2004, 20:296-299. 2443825, 15446759.
3. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 2011, The Cochrane Collaboration: [Updated March 2011], [http://www.cochrane-handbook.org].
4. Balshem H, Stevens A, Ansari M, Norris S, Kansagara D, Shamliyan T, Chou R, Chung M, Moher D, Dickersin K. Finding grey literature evidence and assessing for outcome and analysis reporting biases when comparing medical interventions. AHRQ and the Effective Health Care Program. In Methods Guide for Effectiveness and Comparative Effectiveness Reviews 2013, 19-20. Rockville: Agency for Healthcare Research and Quality: AHRQ Publication No 10(14)-EHC063-EF.
5. Mullan RJ, Flynn DN, Carlberg B, Tleyjeh IM, Kamath CC, LaBella ML, Erwin PJ, Guyatt GH, Montori VM. Systematic reviewers commonly contact study authors but do so with limited rigor. J Clin Epidemiol 2009, 62:138-142. 10.1016/j.jclinepi.2008.08.002, 19013767.
6. Chou R, Cottrell EB, Wasson N, Rahman B, Guise J-M. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013, 158:101-108. 10.7326/0003-4819-158-2-201301150-00574, 23183613.
7. Chou R, Cottrell EB, Wasson N, Rahman B, Guise J-M. Screening for Hepatitis C Virus Infection in Adults. Comparative Effectiveness Review No. 69. (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I.) 2012, Agency for Healthcare Research and Quality: Rockville.
8. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013, 158:807-820. 10.7326/0003-4819-158-11-201306040-00005, 23732714.
9. Attallah AM, Abdallah SO, Attallah AA, Omran MM, Farid K, Nasif WA, Shiha GE, Abdel-Aziz AA, Rasafy N, Shaker YM. Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients. Ann Hepatol 2013, 12:44-53.
10. Attallah AM, Omran MM, Farid K, El-Bendary M, Emran TM, Albannan MS, El-Dosoky I. Development of a novel score for liver fibrosis staging and comparison with eight simple laboratory scores in large numbers of HCV-monoinfected patients. Clin Chim Acta 2012, 413:1725-1730. 10.1016/j.cca.2012.06.031, 22759976.
11. Ben Jazia E, Kaabia N, Benabdelkader A, Khalifa M, Harrabi I, Braham A, Bahri F, Letaief A. Noninvasive fibrosis markers for the prediction of significant fibrosis in patients with chronic hepatitis C virus infection in Tunisia. Infect Dis Clin Pract (Baltim Md) 2009, 17:385-387.
12. Cheung RC, Currie S, Shen H, Bini EJ, Ho SB, Anand BS, Hu K-Q, Wright TL, Morgan TR. Group ftVH-S: Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice?. J Clin Gastroenterol 2008, 42:827-834. 10.1097/MCG.0b013e318046ea9a, 18285716.
13. Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MD, Grigorescu M. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessment in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon 2012, 12:177-184. 10.5812/hepatmon.5106, 3339417, 22550525.
14. Ehsan N, Badr M, Raouf A, Gamal B. Correlation between liver biopsy findings and different serum biochemical tests in staging fibrosis in Egyptian patients with chronic hepatitis C virus infection. Arab J Gastroenterol 2008, 9:7-12.
15. El-mezayen HA, El SAT, Shiha GE. Role of hyaluronic acid, its degrading enzymes, degradation products, and ferritin in the assessment of fibrosis stage in Egyptian patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2013, 25:69-76. 10.1097/MEG.0b013e3283594924, 23011038.
16. Guechot J, Trocme C, Renversez J-C, Sturm N, Zarski J-P. Group AHEFS: Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clin Chem Lab Med 2012, 50:693-699.
17. Iacobellis A, Fusilli S, Mangia A, Clemente R, Festa V, Giacobbe A, Facciorusso D, Niro G, Conoscitore P, Andriulli A. Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis. Aliment Pharmacol Ther 2005, 22:769-774. 10.1111/j.1365-2036.2005.02633.x, 16225484.
18. Iacobellis A, Mangia A, Leandro G, Clemente R, Festa V, Attino V, Ricciardi R, Giacobbe A, Facciorusso D, Andriulli A. External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis. Am J Gastroenterol 2005, 100:868-873. 10.1111/j.1572-0241.2005.40881.x, 15784034.
19. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, Morel F, Zarski JP. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gast 2004, 99:271-279.
20. Mossong J, Bill S, Hawotte K, Gilson G, Knolle U, Weber J, Roskams T, Arendt V. Predicting significant fibrosis in hepatitis C patients in Luxembourg using serological markers. Bull Soc Sci Med Grand Duche Luxemb 2011, 1:19-30.
21. Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, Sugimoto K, Murata K, Nakano T. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005, 11:476-481.
22. Sebastiani G, Vario A, Guido M, Alberti A. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Vir Hep 2008, 15:212-218.
23. Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther 2011, 34:1202-1216. 10.1111/j.1365-2036.2011.04861.x, 21981787.
24. Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther 2012, 35:92-104. 10.1111/j.1365-2036.2011.04897.x, 22035045.
25. Stibbe KJM, Verveer C, Francke J, Hansen BE, Zondervan PE, Kuipers EJ, De Knegt RJ, Van Vuuren AJ. Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroenterol 2011, 46:962-972. 10.3109/00365521.2011.574725, 21623677.
26. Adler M, Gulbis B, Moreno C, Evrard S, Verset G, Golstein P, Frotscher B, Nagy N, Thiry P. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology 2008, 47:762-763. 10.1002/hep.22085, 18220307.
27. Ahmad W, Ijaz B, Javed FT, Gull S, Kausar H, Sarwar MT, Asad S, Shahid I, Sumrin A, Khaliq S, Jahan S, Pervaiz A, Hassan S. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol 2011, 11:44. 10.1186/1471-230X-11-44, 3098184, 21507271.
28. Amorim TG, Staub GJ, Lazzarotto C, Silva AP, Manes J, Da Graca Ferronato M, Shiozawa MB, Narciso-Schiavon JL, Dantas-Correa EB, De Lucca Schiavon L. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C. Ann Hepatol 2012, 11:855-861.
29. Arabul M, Aslan F, Alper E, Akpinar Z, Celik M, Kandemir A, Vatansever S, Unsal B. Simple non-invasive markers as a predictor of fibrosis and viral response in chronic hepatitis C patients. Turk J Gastroenterol 2012, 23:538-545.
30. Bota S, Sirli R, Sporea I, Focsa M, Popescu A, Danila M, Strain M, Sendroiu M, Deleanu A, Dan I. A new scoring system for prediction of fibrosis in chronic hepatitis C. Hepat Mon 2011, 11:548-555. 3212757, 22087193.
31. Bourliere M, Penaranda G, Ouzan D, Renou C, Botta-Fridlund D, Tran A, Rosenthal E, Wartelle-Bladou C, Delasalle P, Oules V, Portal I, Castellani P, Lecomte L, Rosenthal-Alliere MA, Halfon P. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther 2008, 28:458-467. 10.1111/j.1365-2036.2008.03742.x, 18498446.
32. Boursier J, Bacq Y, Halfon P, Leroy V, De Ledinghen V, De Muret A, Bourlière M, Sturm N, Foucher J, Oberti F, Rousselet MC, Cales P. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2009, 21:28-38. 10.1097/MEG.0b013e32830cebd7, 19060630.
33. Boursier J, De Ledinghen V, Zarski J-P, Rousselet M-C, Sturm N, Foucher J, Leroy V, Fouchard-Hubert I, Bertrais S, Gallois Y, Oberti F, Dib N, Cales P. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011, 106:1255-1263. 10.1038/ajg.2011.100, 21468012.
34. Burton MJ, Sunesara I, Penman A, Pham H, Oliver N, Young CA, McGloster N, McGuire BM. Comparing the aspartate aminotransferase (AST) to platelet ratio index (APRI) between African American and white veterans with chronic hepatitis C. South Med J 2011, 104:309-314. 10.1097/SMJ.0b013e318213cf52, 21606706.
35. Calès P, Boursier J, Bertrais S, Oberti F, Gallois Y, Fouchard-Hubert I, Dib N, Zarski JP, Rousselet MC, Multicentric G. Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clin Biochem 2010, 43:1315-1322. 10.1016/j.clinbiochem.2010.08.010, 20713037.
36. Calès P, Boursier J, De Lédinghen V, Halfon P, Bacq Y, Leroy V, Dib N, Oberti F, Sawadogo A, Rousselet MC, Lunel F. Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. Gastroenterol Clin Biol 2008, 32:1050-1060. 10.1016/j.gcb.2008.09.017, 19019606.
37. Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet M, Konate A, Gallois Y, Ternisien C, Chevailler A, Lunel F. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005, 42:1373-1381. 10.1002/hep.20935, 16317693.
38. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350. 10.1053/j.gastro.2004.11.018, 15685546.
39. Cheung KJ, Tilleman K, Deforce D, Colle I, Moreno C, Gustot T, Van Vlierberghe H. Usefulness of a novel serum proteome-derived index FI-PRO (fibrosis-protein) in the prediction of fibrosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2011, 23:701-710. 10.1097/MEG.0b013e3283471b74, 21623191.
40. Cobbold J, Crossey M, Colman P, Goldin R, Murphy P, Patel N, Fitzpatrick J, Vennart W, Thomas H, Cox I, Taylor-Robinson S. Optimal combinations of ultrasound-based and serum markers of disease severity in patients with chronic hepatitis C. J Viral Hepat 2010, 17:537-545.
41. Cross TJ, Calvaruso V, Maimone S, Carey I, Chang TP, Pleguezuelo M, Manousou P, Quaglia A, Grillo F, Dhillon AP, Dusheiko GM, Burroughs AK, Harrison PM. Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. J Viral Hepat 2010, 17:546-546.
42. Cross TJS, Rizzi P, Berry PA, Bruce M, Portmann B, Harrison PM. King's Score: an accurate marker of cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2009, 21:730-738. 10.1097/MEG.0b013e32830dfcb3, 19430302.
43. Deghady A, Abdou A, El-Neanaey WA, Diab I. Association of genetic polymorphism -670A > G in the Fas gene and serum markers AST platelet ratio index, AST/ALT with significant fibrosis and cirrhosis in chronic hepatitis C. Genet Test Mol Biomarkers 2012, 16:531-535. 10.1089/gtmb.2011.0098, 22352690.
44. El-Sayed R, Fahmy M, El Koofy N, El-Raziky M, El-Hawary M, Helmy H, El-Akel W, El-Hennawy A, El-Karaksy H. Can aspartate aminotransferase to platelet ratio index replace liver biopsy in chronic hepatitis C?. Trop Gastroenterol 2011, 32:267-272.
45. Fabris C, Smirne C, Toniutto P, Colletta C, Rapetti R, Minisini R, Falleti E, Leutner M, Pirisi M. Usefulness of six non-proprietary indirect markers of liver fibrosis in patients with chronic hepatitis C. Clin Chem Lab Med 2008, 46:253-259.
46. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC, Group H-CT. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008, 47:789-798. 10.1002/hep.22099, 18175357.
47. Fontanges T, Bailly F, Trepo E, Chevallier M, Maynard-Muet M, Nalet B, Beorchia S, Pillon D, Moindrot H, Froissart B, Slaoui M, Tinel X, Pradat P, Trepo C. Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C. Gastroenterol Clin Biol 2008, 32:858-865. 10.1016/j.gcb.2008.05.019, 18775614.
48. Fouad SA, Esmat S, Omran D, Rashid L, Kobaisi MH. Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection. World J Gastroenterol 2012, 18:2988-2994. 10.3748/wjg.v18.i23.2988, 3380327, 22736923.
49. Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. Comparison of ELF. FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 2010, 10:103.
50. Gabrielli GB, Capra F, Casaril M, Squarzoni S, Tognella P, Dagradi R, De Maria E, Colombari R, Corrocher R, De Sandre G. Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis. Clin Chim Acta 1997, 265:21-31. 10.1016/S0009-8981(97)00103-4, 9352126.
51. Gara N, Zhao X, Kleiner DE, Liang TJ, Hoofnagle JH, Ghany MG. Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2013, 11:303-308. el, 10.1016/j.cgh.2012.10.044, 3642246, 23142332.
52. Giannini E, Testa R. Noninvasive diagnosis of fibrosis: the truth is rarely pure and never simple. Hepatology 2003, 38:1312-1313.
53. Grigorescu M, Rusu M, Neculoiu D, Radu C, Serban A, Catanas M, Grigorescu MD. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience. J Gastrointestin Liver Dis 2007, 16:31-37.
54. Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, Tran A, Botta D, Renou C, Brechot M, Degott C, Paradis V. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007, 46:395-402.
55. Halfon P, Penaranda G, Renou C, Bourliere M. External validation of FibroIndex. Hepatology 2007, 46:280-281. author reply 281-282.
56. Hsieh YY, Tung SY, Lee K, Wu CS, Wei KL, Shen CH, Chang TS, Lin YH. Routine blood tests to predict liver fibrosis in chronic hepatitis C. World J Gastroenterol 2012, 18:746-753. 10.3748/wjg.v18.i8.746, 3286137, 22371634.
57. Ichino N, Osakabe K, Nishikawa T, Sugiyama H, Kato M, Kitahara S, Hashimoto S, Kawabe N, Harata M, Nitta Y, Murao M, Nakano T, Arima Y, Shimazaki H, Suzuki K, Yoshioka K. A new index for non-invasive assessment of liver fibrosis. World J Gastroenterol 2010, 16:4809-4816. 10.3748/wjg.v16.i38.4809, 2955250, 20939109.
58. Imbert-Bismut F, Ratziu V. Laurence Pieroni L, Charlotte F, Benhamou Y, Poynard T, Group M: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075. 10.1016/S0140-6736(00)04258-6, 11297957.
59. Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005, 40:867-872. 10.1080/00365520510015674, 16109665.
60. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber RE. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005, 41:1376-1382. 10.1002/hep.20717, 15915455.
61. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, Sánchez-Avila F, Vargas-Vorácková F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008, 7:350-357.
62. Lu SN, Wang JH, Liu SL, Hung CH, Chen CH, Tung HD, Chen TM, Huang WS, Lee CM, Chen CC, Changchien CS. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006, 107:2212-2222. 10.1002/cncr.22242, 17019738.
63. Martinez SM, Fernández-Varo G, González P, Sampson E, Bruguera M, Navasa M, Jiménez W, Sánchez-Tapias JM, Forns X. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther 2011, 33:138-148. 10.1111/j.1365-2036.2010.04500.x, 21083589.
64. Morali G, Maor Y, Klar R, Braun M, Ari ZB, Bujanover Y, Zuckerman E, Boger S, Halfon P. Fibrotest-Actitest: the biochemical marker of liver fibrosis-the Israeli experience. Isr Med Assoc J 2007, 9:588-591.
65. Morra R, Munteanu M, Bedossa P, Dargere D, Janneau JL, Paradis V, Ratziu V, Charlotte F, Thibault V, Imbert-Bismut F, Poynard T. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007, 26:847-858. 10.1111/j.1365-2036.2007.03427.x, 17767469.
66. Omran MM, Farid K, Emran TM, Attallah AA. Fibro-(alpha) score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C patients. Arab J Gastroenterol 2011, 12:74-79. 10.1016/j.ajg.2011.04.006, 21684477.
67. Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H, Ferraz ML. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006, 26:1095-1099. 10.1111/j.1478-3231.2006.01356.x, 17032410.
68. Park SH, Kim CH, Kim DJ, Suk KT, Park JH, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Park HY, Kim YB. Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C. Clin Biochem 2011, 44:1396-1399. 10.1016/j.clinbiochem.2011.08.1151, 21971609.
69. Park JJ, Park JY, Kimdo Y, Park YN, Ahn SH, Chon CY, Han KH. Prediction of significant fibrosis in chronic hepatitis C patients with normal ALT. Hepatogastroenterology 2011, 58:1321-1327. 10.5754/hge11041, 21937403.
70. Parkes J, Guha I, Roderick P, Harris S, Cross R, Manos M, Irving W, Zaitoun A, Wheatley M, Ryder S, Rosenberg W. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepatitis 2010, 18:23-31.
71. Patel K, Benhamou Y, Yoshida EM, Kaita KD, Zeuzem S, Torbenson M, Pulkstenis E, Subramanian GM, McHutchison JG. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Vir Hep 2009, 16:178-186.
72. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D. Degos F, for the Gcg: Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Vir Hep 2002, 9:128-133.
73. Poynard T, McHutchison J, Manns M, Myers R, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003, 38:481-492.
74. Rosenberg W, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur M. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127:1704-1713. 10.1053/j.gastro.2004.08.052, 15578508.
75. Schneider AR, Teuber G, Kriener S, Caspary WF. Noninvasive assessment of liver steatosis, fibrosis and inflammation in chronic hepatitis C virus infection. Liver Int 2005, 25:1150-1155. 10.1111/j.1478-3231.2005.01164.x, 16343065.
76. Schneider AR, Teuber G, Paul K, Nikodem A, Duesterhoeft M, Caspary WF, Stein J. Patient age is a strong independent predictor of 13C-aminopyrine breath test results: a comparative study with histology, duplex-Doppler and a laboratory index in patients with chronic hepatitis C virus infection. Clin Exp Pharmacol Physiol 2006, 33:300-304. 10.1111/j.1440-1681.2006.04365.x, 16620291.
77. Shlomai A, Halfon P, Goldiner I, Zelber-Sagi S, Halpern Z, Oren R, Bruck R. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2013, 20:95-102. 10.1111/j.1365-2893.2012.01628.x, 23301544.
78. Sirli R, Sporea I, Bota S, Popescu A, Cornianu M. A comparative study of non-invasive methods for fibrosis assessment in chronic HCV infection. Hepat Mon 2010, 10:88-94. 3270362, 22312379.
79. Snyder N, Gajula L, Xiao S-Y, Grady J, Luxon B, Lau DT-Y, Soloway R, Petersen J. APRI: An easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006, 40:535-542. 10.1097/00004836-200607000-00013, 16825937.
80. Snyder N, Nguyen A, Gajula L, Soloway R, Xiao SY, Lau DTY, Petersen J. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clin Chim Acta 2007, 381:119-123. 10.1016/j.cca.2007.02.046, 17442291.
81. Testa R, Testa E, Giannini E, Borro P, Milazzo S, Isola L, Ceppa P, Lantieri PB, Risso D. Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. J Int Med 2006, 260:142-150.
82. Borsoi Viana MS, Takei K, Collarile Yamaguti DC, Guz B, Strauss E. Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. Ann Hepatol 2009, 8:26-31.
83. Westin J, Ydreborg M, Islam S, Alsio A, Dhillon AP, Pawlotsky JM, Zeuzem S, Schalm SW, Ferrari C, Neumann AU, Hellstrand K, Lagging M. A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C infection. Scand J Gastroenterol 2008, 43:78-80.
84. Wilson L, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, Mehta S, Kirk G, Nelson K, Afdhal N, Thomas D. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology 2006, 43:788-795. 10.1002/hep.21091, 16557548.
85. Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): usefulness in patients with chronic liver disease. Hepat Mon 2011, 11:103-107. 3206675, 22087126.
86. Zarski J-P, Sturm N, Guechot J, Paris A, Zafrani E-S, Asselah T, Boisson R-C, Bosson J-L, Guyader D, Renversez J-C, Bronowicki JP, Gelineau MC, Tran A, Trocme C, De Ledinghen V, Lasnier E, Poujol-Robert A, Ziegler F, Bourliere M, Voitot H, Larrey D, Rosenthal-Allieri MA, Fourchard Hubert I, Bailly F, Vaubourdolle M. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012, 56:55-62. 10.1016/j.jhep.2011.05.024, 21781944.
87. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994, 271:703-707. 10.1001/jama.1994.03510330081039, 8309035.
88. Selph S, Chou R. Impact of Contacting Study Authors on Systematic Review Conclusions: Diagnostic Tests for Hepatic Fibrosis. Research White Paper. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2012-00014-I). AHRQ Publication No. 14-EHC004-EF 2014, Agency for Healthcare Research and Quality: Rockville.